Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8. doi: 10.1016/j.chom.2018.12.001.

2.

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.

Horwitz JA, Bar-On Y, Lu CL, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS, Gazumyan A, Zolla-Pazner S, Nussenzweig MC.

Cell. 2017 Aug 10;170(4):637-648.e10. doi: 10.1016/j.cell.2017.06.048. Epub 2017 Jul 27.

3.

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.

Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, Shimeliovich I, Patel R, Burke L, Cohen YZ, Hadrigan S, Settler A, Witmer-Pack M, West AP Jr, Juelg B, Keler T, Hawthorne T, Zingman B, Gulick RM, Pfeifer N, Learn GH, Seaman MS, Bjorkman PJ, Klein F, Schlesinger SJ, Walker BD, Hahn BH, Nussenzweig MC, Caskey M.

Nature. 2016 Jul 28;535(7613):556-60. Epub 2016 Jun 22.

4.

Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2016 Jul 28;535(7613):580. doi: 10.1038/nature17642. Epub 2016 Mar 23. No abstract available.

PMID:
27007847
5.

Structural basis for germline antibody recognition of HIV-1 immunogens.

Scharf L, West AP, Sievers SA, Chen C, Jiang S, Gao H, Gray MD, McGuire AT, Scheid JF, Nussenzweig MC, Stamatatos L, Bjorkman PJ.

Elife. 2016 Mar 21;5. pii: e13783. doi: 10.7554/eLife.13783.

6.

HIV-specific B cell response in patients with broadly neutralizing serum activity.

Scheid JF.

Science. 2015 Dec 4;350(6265):1175. doi: 10.1126/science.aad7133. No abstract available.

PMID:
26785466
7.

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC.

PLoS Pathog. 2015 Oct 30;11(10):e1005238. doi: 10.1371/journal.ppat.1005238. eCollection 2015 Oct.

8.

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.

Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS; NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP Jr, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD.

Cell. 2015 Jun 4;161(6):1280-92. doi: 10.1016/j.cell.2015.05.007. Epub 2015 May 21.

9.

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2015 Jun 25;522(7557):487-91. doi: 10.1038/nature14411. Epub 2015 Apr 8. Erratum in: Nature. 2016 Jul 28;535(7613):580.

10.

Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient.

Freund NT, Scheid JF, Mouquet H, Nussenzweig MC.

J Immunol Methods. 2015 Mar;418:61-5. doi: 10.1016/j.jim.2015.01.011. Epub 2015 Feb 7.

PMID:
25667013
11.

HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.

McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L.

Science. 2014 Dec 12;346(6215):1380-1383. doi: 10.1126/science.1259206.

12.

A robust pipeline for rapid production of versatile nanobody repertoires.

Fridy PC, Li Y, Keegan S, Thompson MK, Nudelman I, Scheid JF, Oeffinger M, Nussenzweig MC, Fenyö D, Chait BT, Rout MP.

Nat Methods. 2014 Dec;11(12):1253-60. doi: 10.1038/nmeth.3170. Epub 2014 Nov 2.

13.

Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.

Scharf L, Scheid JF, Lee JH, West AP Jr, Chen C, Gao H, Gnanapragasam PN, Mares R, Seaman MS, Ward AB, Nussenzweig MC, Bjorkman PJ.

Cell Rep. 2014 May 8;7(3):785-95. doi: 10.1016/j.celrep.2014.04.001. Epub 2014 Apr 24.

14.

Structural insights on the role of antibodies in HIV-1 vaccine and therapy.

West AP Jr, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC.

Cell. 2014 Feb 13;156(4):633-48. doi: 10.1016/j.cell.2014.01.052. Review.

15.

Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.

Malbec M, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A, Scheid JF, Eden C, Mouquet H, Nussenzweig MC, Schwartz O.

J Exp Med. 2013 Dec 16;210(13):2813-21. doi: 10.1084/jem.20131244. Epub 2013 Nov 25.

16.

Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.).

Gaebler C, Gruell H, Velinzon K, Scheid JF, Nussenzweig MC, Klein F.

J Immunol Methods. 2013 Nov 29;397(1-2):47-54. doi: 10.1016/j.jim.2013.09.003. Epub 2013 Sep 13.

17.

Antibodies in HIV-1 vaccine development and therapy.

Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC.

Science. 2013 Sep 13;341(6151):1199-204. doi: 10.1126/science.1241144. Review.

18.

Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.

Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang GY, Joyce MG, Kwon YD, Longo NS, Louder MK, Luongo T, McKee K, Schramm CA, Skinner J, Yang Y, Yang Z, Zhang Z, Zheng A, Bonsignori M, Haynes BF, Scheid JF, Nussenzweig MC, Simek M, Burton DR, Koff WC; NISC Comparative Sequencing Program, Mullikin JC, Connors M, Shapiro L, Nabel GJ, Mascola JR, Kwong PD.

Immunity. 2013 Aug 22;39(2):245-58. doi: 10.1016/j.immuni.2013.04.012. Epub 2013 Aug 1.

19.

Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC.

Cell. 2013 Mar 28;153(1):126-38. doi: 10.1016/j.cell.2013.03.018.

20.

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.

McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L.

J Exp Med. 2013 Apr 8;210(4):655-63. doi: 10.1084/jem.20122824. Epub 2013 Mar 25.

21.

Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.

Scharf L, West AP Jr, Gao H, Lee T, Scheid JF, Nussenzweig MC, Bjorkman PJ, Diskin R.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6049-54. doi: 10.1073/pnas.1303682110. Epub 2013 Mar 22.

22.

Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L.

PLoS Pathog. 2013 Jan;9(1):e1003106. doi: 10.1371/journal.ppat.1003106. Epub 2013 Jan 3. Erratum in: PLoS Pathog. 2013 Jul;9(9). doi:10.1371/annotation/ed7c0148-97eb-4416-824d-6e6d1aaeceef.

23.

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies.

Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PN, Spencer DI, Seaman MS, Schuitemaker H, Feizi T, Nussenzweig MC, Bjorkman PJ.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):E3268-77. doi: 10.1073/pnas.1217207109. Epub 2012 Oct 30.

24.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio P, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC.

Nature. 2012 Dec 6;492(7427):118-22. doi: 10.1038/nature11604. Epub 2012 Oct 24.

25.

Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus.

Sather DN, Carbonetti S, Kehayia J, Kraft Z, Mikell I, Scheid JF, Klein F, Stamatatos L.

J Virol. 2012 Dec;86(23):12676-85. doi: 10.1128/JVI.01893-12. Epub 2012 Sep 12.

26.

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.

Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fätkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC.

J Exp Med. 2012 Jul 30;209(8):1469-79. doi: 10.1084/jem.20120423. Epub 2012 Jul 23.

27.

Enhanced HIV-1 neutralization by antibody heteroligation.

Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):875-80. doi: 10.1073/pnas.1120059109. Epub 2012 Jan 4.

28.

Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Diskin R, Scheid JF, Marcovecchio PM, West AP Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ.

Science. 2011 Dec 2;334(6060):1289-93. doi: 10.1126/science.1213782. Epub 2011 Oct 27.

29.

Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells.

Scheid JF, Mouquet H, Kofer J, Yurasov S, Nussenzweig MC, Wardemann H.

Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18044-8. doi: 10.1073/pnas.1113395108. Epub 2011 Oct 24.

30.

Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.

Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC.

PLoS One. 2011;6(9):e24078. doi: 10.1371/journal.pone.0024078. Epub 2011 Sep 8.

31.

Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC.

Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227. Epub 2011 Jul 14.

32.

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.

Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J, Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK, Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC.

Nature. 2010 Sep 30;467(7315):591-5. doi: 10.1038/nature09385.

33.

Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.

Pietzsch J, Scheid JF, Mouquet H, Klein F, Seaman MS, Jankovic M, Corti D, Lanzavecchia A, Nussenzweig MC.

J Exp Med. 2010 Aug 30;207(9):1995-2002. doi: 10.1084/jem.20101176. Epub 2010 Aug 2.

34.

Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD.

Science. 2010 Aug 13;329(5993):811-7. doi: 10.1126/science.1192819. Epub 2010 Jul 8.

35.

Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.

Pietzsch J, Scheid JF, Mouquet H, Seaman MS, Broder CC, Nussenzweig MC.

J Virol. 2010 May;84(10):5032-42. doi: 10.1128/JVI.00154-10. Epub 2010 Mar 10.

36.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM, Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD, Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC.

Nature. 2009 Apr 2;458(7238):636-40. doi: 10.1038/nature07930. Epub 2009 Mar 15.

PMID:
19287373
37.

A method for identification of HIV gp140 binding memory B cells in human blood.

Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, Seaman MS, Mascola JR, Wyatt RT, Wardemann H, Nussenzweig MC.

J Immunol Methods. 2009 Apr 15;343(2):65-7. doi: 10.1016/j.jim.2008.11.012. Epub 2008 Dec 25.

Supplemental Content

Loading ...
Support Center